 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...4748495051525354555657...7475» |
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial completion date: Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion (clinicaltrials.gov) - Aug 20, 2019
P4, N=27, Completed, Sponsor: Nagoya City University
Recruiting --> Completed | Trial completion date: Sep 2019 --> Mar 2019
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial completion date: Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD. (clinicaltrials.gov) - Aug 20, 2019
P4, N=78, Completed, Sponsor: Nagoya City University
Recruiting --> Completed | Trial completion date: Sep 2019 --> Mar 2019 Recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2019
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion (clinicaltrials.gov) - Aug 19, 2019
P4, N=100, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. (Pubmed Central) - Aug 17, 2019
Recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2019 In this 3-year randomized trial of 40 eyes with DME, there was no evidence that combination therapy with ranibizumab and TRP improved visual outcomes or reduced treatment burden compared with ranibizumab alone.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-World Evidence: The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry. (Pubmed Central) - Aug 17, 2019
A proportion of patients, on average 2.6%, experienced a sustained clinically significant IOP rise with these drugs overall compared with 1.5% in the fellow untreated eyes. However, such an increase was not seen with aflibercept.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). (Pubmed Central) - Aug 17, 2019
However, such an increase was not seen with aflibercept. Treatment with RBZ+PRP was more effective than PRP monotherapy for NV regression in HR-PDR participants over 12 months.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Major factors affecting intraocular pressure spike after intravitreal ranibizumab injection: Vitreous reflux and its amount. (Pubmed Central) - Aug 17, 2019
The major factor affecting short-term postinjection intraocular pressure elevation was vitreous reflux, and intraocular pressure levels increased as the amount of vitreous reflux decreased. Vitreous reflux and its amount decreased as the total number of intravitreal injection increased.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Anti-VEGF therapy for diabetic macular edema. From theory to clinical practice (Pubmed Central) - Aug 17, 2019
Vitreous reflux and its amount decreased as the total number of intravitreal injection increased. Aflibercept can be used as first-choice drug for treatment of DME patients (both therapy-naïve and unresponsive to previous ranibizumab therapy) to improve anatomical parameters and visual function.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Impact of antiangiogenic therapy on ocular blood flow and microcirculation in diabetic macular edema (Pubmed Central) - Aug 17, 2019
The study revealed no negative effects of the angiogenesis inhibitor ranibizumab on retinal microcirculation or ocular blood flow. The registered changes in blood flow may indicate improvement of hemodynamic parameters after resorption of macular edema.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Changes in intraocular pressure after intravitreal injections (Pubmed Central) - Aug 17, 2019
The registered changes in blood flow may indicate improvement of hemodynamic parameters after resorption of macular edema. The revealed changes can serve as a pathophysiological model for studying changes of biometric parameters of anterior and posterior eye segments and biomechanical properties of fibrous tunic.
- | Journal: Intravitreal Ziv-Aflibercept: A Comprehensive Review. (Pubmed Central) - Aug 16, 2019
...Neovascular age-related macular degeneration (nAMD) is sight-threatening, but can be treated by three currently utilized, intravitreally administered drugs: aflibercept, bevacizumab, and ranibizumab...Clinical trials of ziv-aflibercept in other neovascular disorders such as diabetic macular edema (DME) and retinal vein occlusion (RVO) have shown similar results. Further prospective, randomized studies of ziv-aflibercept are needed, particularly in eyes with nAMD.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration. (Pubmed Central) - Aug 16, 2019
In all patients who were nonresponders to aflibercept, injection interval could not be extended. A switchback from ranibizumab to aflibercept may be beneficial in some patients with AMD who exhibit tachyphylaxis to aflibercept.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY. (Pubmed Central) - Aug 15, 2019
Best-corrected visual acuity gained at the end of the RADIANCE trial was sustained over additional 36 months of follow-up. Few patients required further treatment and no new safety concerns were observed.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION. (Pubmed Central) - Aug 15, 2019
There was no difference between the aflibercept and ranibizumab treatments in terms of visual acuity improvement after 12 months in patients with Type 3 neovascularization. However, geographic atrophy developed more frequently in the aflibercept-treated group.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Structural changes in the ocular anterior segment against elevation of intraocular pressure after repeated intravitreal injections (Pubmed Central) - Aug 15, 2019
However, geographic atrophy developed more frequently in the aflibercept-treated group. The revealed changes were transient in nature and did not require any corrections since all parameters returned to baseline after each injection.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: The role of anti-VEGF therapy in geographic atrophy progression (Pubmed Central) - Aug 15, 2019
Based on literature data, GA in AMD can be subtyped as follows: drusen-related; associated with choroidal neovascularization; secondary to anti-VEGF treatment; subsequent to collapse of RPE detachment and RPE rupture. Comparison of functional results of various examination methods suggests that presence of GA in patients with exudative AMD cannot be a counter-indication for anti-VEGF therapy, but these patients require careful monitoring involving high-technology methods of eye fundus visualization and personalized approach when choosing the treatment regimen.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Topographic Correspondence of Macular Atrophy with Choroidal Neovascularization in Ranibizumab Treated Eyes of the TREX-AMD Trial. (Pubmed Central) - Aug 11, 2019
In ranibizumab-treated eyes with NVAMD, more MA lesions develop within the region of baseline-CNV (Type-I, CNV-based MA) than outside (Type-II, CNV-independent MA). Baseline-MA also tends to be located within regions of CNV in the pre-treatment phase.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Review, Journal: The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis. (Pubmed Central) - Aug 11, 2019
Despite the growing preference for the T&E regimen, there is limited head-to-head evidence comparing dosing strategies. The evidence available however, suggests that at 12 months, T&E is comparable to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study. (Pubmed Central) - Aug 9, 2019
The evidence available however, suggests that at 12 months, T&E is comparable to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab. Aflibercept switch therapy seems to be effective on large PED in patients previously treated with pro re nata ranibizumab.
- | Axpaxli (intravitreal axitinib implant) / Ocular Therap
Enrollment change: CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov) - Aug 8, 2019
P1, N=24, Recruiting, Sponsor: Ocular Therapeutix, Inc.
Aflibercept switch therapy seems to be effective on large PED in patients previously treated with pro re nata ranibizumab. N=18 --> 24
- | ASP8232 / Astellas, Lucentis (ranibizumab) / Roche, Novartis
Clinical, P2 data, Journal: Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema. (Pubmed Central) - Aug 8, 2019
P2
Furthermore, combination therapy did not provide additional benefit to treatment with ranibizumab alone, which significantly reduced CST and improved BCVA.Trial registration clinicaltrials.gov; NCT02302079. Registered on November 26, 2014.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Real-life experience of ranibizumab for diabetic macular edema in Taiwan. (Pubmed Central) - Aug 8, 2019
Treatment for DME with at least three monthly ranibizumab loading injections, with or without other supplementary treatments, is effective at 12 months thereafter. Two monthly reinjections of ranibizumab, while not significantly increasing vision, may have a role in preventing visual loss.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema. (Pubmed Central) - Aug 8, 2019
Two monthly reinjections of ranibizumab, while not significantly increasing vision, may have a role in preventing visual loss. Adding steroid to routine anti-VEGF treatment is an effective way of treatment method for resistant DME.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal: Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration. (Pubmed Central) - Aug 8, 2019
Significant differences regarding BCVA, central macular thickness, and the number of injections were not found between aflibercept and ranibizumab during the first year following the treat and extend protocol. However, the significantly higher major recurrence rates in the aflibercept group after extending the treatment interval to 10 weeks might suggest that aflibercept should better not to be used in longer than 8 weeks intervals during the first year of treatment.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Head-to-Head: Safety of intravitreal injections: Non-inferiority of bevacizumab compared with ranibizumab. (Pubmed Central) - Aug 7, 2019
However, the significantly higher major recurrence rates in the aflibercept group after extending the treatment interval to 10 weeks might suggest that aflibercept should better not to be used in longer than 8 weeks intervals during the first year of treatment. No abstract available
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-World Evidence: Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry. (Pubmed Central) - Aug 3, 2019
No abstract available This study suggests that all 3 drugs improve VA similarly over 1 year of monotherapy.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-World Evidence: Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study. (Pubmed Central) - Aug 3, 2019
This study suggests that all 3 drugs improve VA similarly over 1 year of monotherapy. The BOREAL study confirms the effectiveness and safety of ranibizumab for the treatment of DME-related visual impairment in routine clinical practice with fewer injections than reported in clinical trials.
- | Lucentis (ranibizumab) / Roche, Novartis, conbercept (KH902) / Chengdu Kanghong
Journal: One-Year Outcomes of Intravitreal Conbercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Aug 3, 2019
The BOREAL study confirms the effectiveness and safety of ranibizumab for the treatment of DME-related visual impairment in routine clinical practice with fewer injections than reported in clinical trials. Intravitreal injections of conbercept appear to be beneficial in patients with nvAMD who exhibit persistent fluid despite previous treatment with ranibizumab.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
PK/PD data, Review, Journal: Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. (Pubmed Central) - Aug 3, 2019
The pharmacokinetic parameters that were collected differ depending on the species that were involved in the studies and on physiological and pathological conditions, such as vitrectomy and lensectomy. Knowledge of the intravitreal pharmacokinetics of the anti-VEGF drugs that were used in clinical practice is of vital importance.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis. (Pubmed Central) - Aug 2, 2019
P4
Patients with prior anti-VEGF therapy who were transitioned to IAI therapy revealed significant anatomic improvements through 6 months.Trial registration Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab (SwapTwo), Trial registration number: NCT02559180. Date of registration: September 24, 2015.https://clinicaltrials.gov/ct2/show/NCT02559180.
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Combination therapy: A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME) (clinicaltrials.gov) - Aug 1, 2019
P2, N=70, Completed, Sponsor: Oxurion
Date of registration: September 24, 2015.https://clinicaltrials.gov/ct2/show/NCT02559180. Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical Trial,Phase I, Clinical Trial,Phase IV, Journal: Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study. (Pubmed Central) - Aug 1, 2019
In patients previously treated with ranibizumab or bevacizumab for macular edema due to nonischemic CRVO, aflibercept increased the macular edema free interval. This may help minimize the treatment burden in patients with recurrent macular edema secondary to nonischemic CRVO.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study. (Pubmed Central) - Aug 1, 2019
Shorter duration of CRVO at baseline was associated with better VA gains. Safety findings were consistent with those reported in previous ranibizumab studies in patients with CRVO.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema. (Pubmed Central) - Aug 1, 2019
P3
Compared with the original baseline, at 1 month after surgery, on average, ranibizumab-treated study eyes experienced mean BCVA improvement (+11.3 letters), whereas sham-treated eyes (-0.5 letters) and fellow eyes (+1.8 and +1.7 letters for ranibizumab and sham, respectively) had a mean BCVA similar to the original baseline. In patients undergoing ranibizumab treatment for DME and who had cataract surgery, an average of 2 lines of vision were gained from the last visit before surgery to 1 month after surgery.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Treated cases of retinopathy of prematurity in Germany : 5-year data from the Retina.net ROP registry (Pubmed Central) - Aug 1, 2019
This needs to be considered when interpreting data such as disease recurrence rates. The risk for late recurrences after anti-VEGF treatment is of particular clinical significance.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Long-term effects of anti-VEGF therapy for retinopathy of prematurity (Pubmed Central) - Aug 1, 2019
Long-term effects of anti-VEGF therapy in ROP differ significantly from alternative treatment options such as laser coagulation. These differences are of relevance for the choice of treatment modality and the follow-up regimen of treated children.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Review, Journal: Review of clinical trials in retinopathy of prematurity : Current state and future perspectives (Pubmed Central) - Aug 1, 2019
Treatment of ROP remains a highly individual decision in which many variables need to be considered. The data discussed in this article can help in decision-making and emphasize the unique characteristics of the available therapeutic approaches, in particular regarding postoperative follow-up.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects. (Pubmed Central) - Aug 1, 2019
The HTRA1 rs11200638 and ARMS2 rs10490924 gene polymorphisms are associated with nAMD among Malaysians. Both gene polymorphisms were also correlated with response to intravitreal ranibizumab therapy based on visual and anatomical outcomes especially the HTRA1 rs11200638 variant.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration (Pubmed Central) - Aug 1, 2019
Cataract surgery combined with IVR treatment yielded significant visual gain in patients with active nAMD. Anatomic results suggest that cataract surgery does not worsen nAMD.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy. (Pubmed Central) - Jul 30, 2019
At 12 months postinjection, ranibizumab treatment could stabilize VA in most PCV patients. The baseline VA, the reduction in subretinal fluids and the greatest lesion diameter were predictive factors for the relative improvement of VA at the final follow-up.
- || Lucentis (ranibizumab) / Roche, Novartis
La @EMA_News aconseja la aprobación de Lucentis de @NovartisSpain - https://t.co/hhuYmK7f2F (Twitter) - Jul 29, 2019
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Regarding comments by Mathis T and Kodjikian L on "Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab". (Pubmed Central) - Jul 28, 2019
The baseline VA, the reduction in subretinal fluids and the greatest lesion diameter were predictive factors for the relative improvement of VA at the final follow-up. No abstract available
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Choroidal neovascularization due to choroidal osteoma treated with anti-vascular endothelial growth factor therapy: An optical coherence tomography angiography study. (Pubmed Central) - Jul 28, 2019
No abstract available Optical coherence tomography angiography seems to be a useful tool in visualizing and distinguishing vascular networks of choroidal osteoma and of choroidal neovascularization secondary to choroidal osteoma better than fluorescein angiography.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Treatment reality with ranibizumab in clinical routine use for patients with diabetic macular edema : 1‑year results of the German POLARIS cohort (Pubmed Central) - Jul 28, 2019
The injection frequency in Germany was lower than in randomized clinical trials. Almost half of the patients received less than 4 injections in the first year of treatment and thus showed an undertreatment compared to the recommendations of German and international medical societies.
- | Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Clinical, Retrospective data, Journal: Anti-Fumarase Antibody as a Predictor of Functional Efficacy of Anti-VEGF Therapy for Diabetic Macular Edema. (Pubmed Central) - Jul 28, 2019
...In this retrospective study, we investigated 52 eyes of 52 DME patients who received intravitreal injections of anti-VEGF drugs (ranibizumab or aflibercept) after blood sampling at baseline...In contrast, the titer was not associated with logMAR VA at 12 months. Anti-fumarase antibody is a novel serum biomarker predicting better functional efficacy of anti-VEGF treatment for DME.
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Anti-VEGF drug interference with VEGF quantitation in the R&D systems human quantikine VEGF ELISA kit. (Pubmed Central) - Jul 28, 2019
Anti-fumarase antibody is a novel serum biomarker predicting better functional efficacy of anti-VEGF treatment for DME. The immunoassay cannot accurately quantitate VEGF in the presence of these VEGF inhibitors as they interfere with the capture and detection of free VEGF.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Newly occurring loss of visual acuity in choroidal osteoma (Pubmed Central) - Jul 26, 2019
secondary CNV. Anti-VEGF IVT represents an approved treatment option.
- | Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Journal: Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Jul 26, 2019
To evaluate the potential of machine learning to predict best-corrected visual acuity (BCVA) outcomes from structural and functional assessments during the initiation phase in patients receiving standardized ranibizumab therapy for neovascular age-related macular degeneration (AMD)...In this large-scale study based on a wide spectrum of morphologic and functional features, baseline BCVA correlated modestly with baseline SD-OCT, whereas functional outcomes were determined by BCVA levels during the initiation phase with a minor influence of fluid-related features. This finding suggests a re-evaluation of current diagnostic imaging features and a search for novel imaging approaches, where machine learning is a promising approach.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: The process of retinal vascularization in retinopathy of prematurity after ranibizumab treatment in China. (Pubmed Central) - Jul 26, 2019
Lighter BW and the severity of ROP are risk factors. Furthermore, repeated injections also increase the risk of retinal peripheral avascular area remaining in ROP patients.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Hollow Microcapsules as Periocular Drug Depot for Sustained Release of Anti-VEGF Protein. (Pubmed Central) - Jul 25, 2019
These positively charged microcapsules were then loaded with anti-VEGF protein ranibizumab using pH dependent permeability switching and protein release from the microcapsules were studied using an in vitro setup. An ex vivo experiment utilizing porcine sclera demonstrated sustained release of ranibizumab over seven days with zero-order kinetics.